Natraj Proteins turns profitable in FY26 with ₹113.51 lakh net profit
- Natraj Proteins posted a net profit of ₹113.51 lakh in FY26, reversing a ₹146.27 lakh loss in FY25.
- Revenue declined 14.1% to ₹10,112.13 lakh, while total expenditure fell 16.0%.
- The 35th AGM is scheduled for September 29, 2026, via VC/OAVM.
- Sharad Kumar Jain seeks re-appointment as Whole-time Director for three years.
*this image is generated using AI for illustrative purposes only.
Natraj Proteins reported a net profit of ₹113.51 lakh for the financial year ended March 31, 2026, reversing a net loss of ₹146.27 lakh in the previous year. Revenue from operations declined to ₹10,112.13 lakh from ₹11,778.29 lakh in FY25.
The company has scheduled its 35th Annual General Meeting (AGM) for Tuesday, September 29, 2026, at 2:00 pm via Video Conferencing or Other Audio-Visual Means (OAVM). Remote e-voting will commence on September 26, 2026, at 9:00 am and conclude on September 28, 2026, at 5:00 pm. The cut-off date for voting entitlement is September 22, 2026.
Financial Performance
The turnaround in profitability was driven by a reduction in total expenditure to ₹10,028.38 lakh from ₹11,944.78 lakh in FY25, despite the decline in revenue. Profit before tax stood at ₹110.58 lakh compared to a loss of ₹117.65 lakh in the prior year. Earnings per share (EPS) were ₹3.03, improving from a loss of ₹3.90 per share in FY25.
| Metric | FY26 | FY25 | Change |
|---|---|---|---|
| Revenue from Operations | ₹10,112.13 lakh | ₹11,778.29 lakh | -14.1% |
| Total Expenditure | ₹10,028.38 lakh | ₹11,944.78 lakh | -16.0% |
| Net Profit/(Loss) | ₹113.51 lakh | (₹146.27) lakh | Turnaround |
| EPS (Basic) | ₹3.03 | (₹3.90) | Improvement |
Key Operational Updates
The Board proposes the re-appointment of Sharad Kumar Jain as Whole-time Director for three years w.e.f. October 1, 2026. Shareholders will also ratify the remuneration of M/s Yogesh Chourasia & Associates as Cost Auditors for FY27. Kailash Chand Sharma retires by rotation and offers himself for re-appointment as Chairman & Managing Director.
The company’s annual capacity remains at 75,000 M.T.P.A. for oilseed crushing and 15,000 M.T.P.A. for edible oil refining. No dividend is recommended for FY26 to retain profits for future purposes.
What the Numbers Show
The profit turnaround occurred despite a 14.1% decline in revenue, indicating significant cost efficiency improvements. Total expenditure fell by 16.0%, outpacing the revenue drop. This divergence suggests operational leverage or reduced input costs contributed more to the bottom line than top-line growth in FY26.
Historical Stock Returns for Natraj Proteins
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | -5.03% | +10.03% | -8.15% | -43.43% |
What specific cost-cutting measures or operational efficiencies enabled Natraj Proteins to reduce total expenditure by 16% despite a 14% revenue decline?
How does the decision to retain all profits without declaring a dividend signal the company's strategic priorities for future expansion or debt reduction?
Will the re-appointment of Sharad Kumar Jain as Whole-time Director introduce new strategic initiatives to reverse the recent trend of declining operational revenue?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
